Ignite Creation Date:
2025-12-25 @ 3:21 AM
Ignite Modification Date:
2025-12-26 @ 1:59 AM
Study NCT ID:
NCT05637905
Status:
UNKNOWN
Last Update Posted:
2022-12-06
First Post:
2022-11-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients
Sponsor:
Assiut University
Organization:
Study Overview
Official Title:
The Predictive Value of Monocyte Chemoattractant Protein -1 in the Development of Cardiovacular Events in Psoriatic Arthritis Patients
Status:
UNKNOWN
Status Verified Date:
2022-11
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1. Evaluate serum levels of (MCP-1) in PsA with or without cardiovascular affaction .
2. Detect subclinical cardiovascular affaction in patients with PsA for early diagnosis and management .
2. Detect subclinical cardiovascular affaction in patients with PsA for early diagnosis and management .
Detailed Description:
Psoriatic arthritis (PSA) is an autoimmune disease arising from the interply between proinflamatory cytokines
\[1\]and external stimuli in genetically predisposed individuals.\[2\]
* The disease is chronic and affects the peripheral joints and may include axial skeleton with or without extrarticular manifestations.\[3\]
* Abnormal activation of the innate and adaptive immune systems contributes to chronic disease processes in both psoriasis and PSA .\[4\] The skin and the joints exhibit a prominent lymphocytic infiltrate consisting of activated CD4+ and CD8+ T cells as well as an increase in neutrophil infiltration\[5\].
Patients with PsA have a higher risk of developing a cardiovascular(CV) events than the general population. This could be attributed to the higher prevalence of traditional cardiovascular risk factors and to the disease characteristics such as systemic inflammation. \[6\] These patients may show asymptomatic cardiomyopathy even in the absence of traditional risk factors \[7\].Cardiac dysfunction is associated with a poor prognosis, increased mortality, and affact socioecenomic function of patients therefore, the diagnosis of the cardiac dysfunction in the asymptomatic phase of the disease \[8\] is important for the timely introduction of therapy \[9\].Monocyte chemotactic protien1(MCP-1) is a member of chemotactic chemokines(CC) which are secreted by immune effector cells and dysfunctional endothelium \[10\].
* The pivotal function of MCP-1 is to attract monocyte in the arterial wall through increased expression of adhesion molecules on their surface that interacts with endothelium\[11\].
* MCP-1 induce maturation of monocyte in the arterial wall ,which then become specialized macrophage in early atheroma and produce tissue factors supporting coagulation and proinflammatory cytokines such as IL-1 and IL-6. It affects the functions of the surrounding immune effector cells in locally thickened intima.\[12\]
* During active disease in psoriatic skin lesions and synovial tissue, activated monocytes represent the major source of proinflammatory mediators, including the chemokine MCP-1 \[13\]. MCP-1 is thought to be involved in the pathogenesis of oedema and bone erosion in patients with PsA \[14\].
\[1\]and external stimuli in genetically predisposed individuals.\[2\]
* The disease is chronic and affects the peripheral joints and may include axial skeleton with or without extrarticular manifestations.\[3\]
* Abnormal activation of the innate and adaptive immune systems contributes to chronic disease processes in both psoriasis and PSA .\[4\] The skin and the joints exhibit a prominent lymphocytic infiltrate consisting of activated CD4+ and CD8+ T cells as well as an increase in neutrophil infiltration\[5\].
Patients with PsA have a higher risk of developing a cardiovascular(CV) events than the general population. This could be attributed to the higher prevalence of traditional cardiovascular risk factors and to the disease characteristics such as systemic inflammation. \[6\] These patients may show asymptomatic cardiomyopathy even in the absence of traditional risk factors \[7\].Cardiac dysfunction is associated with a poor prognosis, increased mortality, and affact socioecenomic function of patients therefore, the diagnosis of the cardiac dysfunction in the asymptomatic phase of the disease \[8\] is important for the timely introduction of therapy \[9\].Monocyte chemotactic protien1(MCP-1) is a member of chemotactic chemokines(CC) which are secreted by immune effector cells and dysfunctional endothelium \[10\].
* The pivotal function of MCP-1 is to attract monocyte in the arterial wall through increased expression of adhesion molecules on their surface that interacts with endothelium\[11\].
* MCP-1 induce maturation of monocyte in the arterial wall ,which then become specialized macrophage in early atheroma and produce tissue factors supporting coagulation and proinflammatory cytokines such as IL-1 and IL-6. It affects the functions of the surrounding immune effector cells in locally thickened intima.\[12\]
* During active disease in psoriatic skin lesions and synovial tissue, activated monocytes represent the major source of proinflammatory mediators, including the chemokine MCP-1 \[13\]. MCP-1 is thought to be involved in the pathogenesis of oedema and bone erosion in patients with PsA \[14\].
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: